Illumina, Inc. $ILMN Stock: Ieq Capital LLC Trims Position

Ieq Capital LLC cut its position in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 10.9% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 238,696 shares of the life sciences company’s stock after selling 29,236 shares during the period. Ieq Capital LLC’s holdings in Illumina were worth $65,326,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of ILMN. BlackRock Inc. purchased a new stake in Illumina in the second quarter worth about $3,374,423,000. Primecap Management Co. CA purchased a new position in Illumina during the 2nd quarter valued at about $617,981,000. Jupiter Topco LLC purchased a new position in Illumina during the 2nd quarter valued at about $358,652,000. Bank of New York Mellon Corp purchased a new position in Illumina during the 2nd quarter valued at about $293,846,000. Finally, Bank of America Corp DE bought a new stake in shares of Illumina in the 2nd quarter valued at about $255,883,000. 89.42% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Jefferies Financial Group set a $235.00 price target on shares of Illumina and gave the stock a “hold” rating in a research report on Monday. Argus lifted their price objective on shares of Illumina from $180.00 to $235.00 and gave the company a “buy” rating in a report on Thursday, September 3rd. TD Cowen lifted their price objective on shares of Illumina from $210.00 to $270.00 and gave the company a “hold” rating in a report on Tuesday, October 13th. Canaccord Genuity Group raised their price objective on Illumina from $205.00 to $300.00 and gave the company a “hold” rating in a research report on Monday, October 19th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Illumina from $320.00 to $300.00 and set an “overweight” rating on the stock in a research report on Friday, October 30th. Nine investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $243.72.

Read Our Latest Analysis on Illumina

Insider Buying and Selling

In other Illumina news, CAO Scott D. Ericksen sold 267 shares of Illumina stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $217.76, for a total transaction of $58,141.92. Following the completion of the sale, the chief accounting officer directly owned 14,029 shares in the company, valued at approximately $3,054,955.04. The trade was a 1.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 98,833 shares of Illumina stock in a transaction that occurred on Wednesday, November 11th. The shares were sold at an average price of $216.87, for a total transaction of $21,433,912.71. Following the sale, the director owned 208,826 shares of the company’s stock, valued at approximately $45,288,094.62. The trade was a 32.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 1,500,628 shares of company stock worth $335,394,565. 2.90% of the stock is owned by insiders.

Illumina Stock Up 2.4%

Illumina stock opened at $215.13 on Thursday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.05 and a current ratio of 2.63. The business’s 50-day simple moving average is $248.55 and its two-hundred day simple moving average is $180.47. The company has a market cap of $32.53 billion, a PE ratio of 36.54, a PEG ratio of 2.75 and a beta of 1.46. Illumina, Inc. has a fifty-two week low of $112.65 and a fifty-two week high of $309.35.

Illumina (NASDAQ:ILMN – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.36 by $0.26. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The firm had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.15 billion. During the same period last year, the business posted $1.34 earnings per share. The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. Equities analysts anticipate that Illumina, Inc. will post 5.43 EPS for the current year.

Illumina Company Profile

(Free Report)

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.

Read More

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.